Genmab — Maj 2018
-
God morgen.
-
44 hhv 28% er det samme som ASH - http://files.shareholder.com/downloads/AMDA-KPIBN/4155053070x0x979926/CC2D43AE-7117-4D7C-ABC8-E3B321A6E811/Genmab_IR_Presentation_9May18.pdf side 12
-
JNJ has a nice overview of their abstracts with links
https://www.prnewswire.com/news-releases/janssen-to-present-new-data-in-urothelial-hematologic-and-prostate-cancers-at-asco-2018-including-best-of-asco-selections-300649958.html?tc=eml_cleartime -
Det er rigtigt Solsen. De 44 hhv 42% er to forskellige perioder. Men det er samme patientgruppe som Sirius. Dog skal man som bekendt være forsigtig med at sammenligne på tværs, især i små studier. Men det ser da lovende ud med 10-12% flere respondenter i sc. Vi får det nok først endeligt afgjort i det store SC vs IV, der kører nu.
-
yes, true. ASCO17 was all about CAR-T and I suspect ASCO18 will not be much different; but I am hoping it will feature more of the negative side and dampen the exuberant enthusiasm we say last year, or in Jan's words, "dampen the irrational CAR-T hysteria"
-
Nyeste reklamevideo https://www.youtube.com/watch?v=gQs_U3vc4Rk
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind